Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Matching-adjusted indirect comparison of Isa-Kd versus Dara-Rd in relapsed multiple myeloma

Joshua Richter • 27 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Carfilzomib Daratumumab Dexamethasone Isatuximab Lenalidomide
CANDOR IKEMA

Joshua Richter, MD, Mount Sinai Medical Center, New York City, NY, shares the findings from a matching-adjusted indirect comparison (MAIC) of isatuximab plus carfilzomib and dexamethasone (Isa-Kd) versus daratumumab plus lenalidomide and dexamethasone (Dara-Rd) in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultant/advisor: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Abbvie, Genentech
Speakers bureau: Janssen, BMS, Sanofi, Adaptive Biotechnologies

More from Joshua Richter

1:33
Updates from the LINKER-MM1 study: linvoseltamab in R/R multiple myeloma
Joshua Richter • 27 Sep 2023
1:14
Prevention & monitoring of infections in patients with multiple myeloma treated with immunotherapies
Joshua Richter • 27 Sep 2023
1:45
The value of teclistamab in R/R myeloma & strategies to mitigate toxicities
Joshua Richter • 27 Sep 2023
1:38
Bridging patients with myeloma to subsequent treatments with chemotherapy & stem cell support
Joshua Richter • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals